ReachMDOptimizing CD19-Targeted Therapies in Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Following participation in this educational activity, hematologists/oncologists, nurses, pharmacists, and other members of the interprofessional team involved in the management of DLBCL patients should be better able to:

• Analyze recent clinical trial data for current and emerging CD19-directed monoclonal antibody therapies and combinations for the treatment of R/R DLBCL across therapeutic lines.
• Analyze recent clinical trial data for current and emerging CD19-directed cellular therapies and combinations for the treatment of R/R DLBCL across therapeutic lines.
• Implement the most recent evidence and best practices for monitoring and mitigating adverse events associated with CD19-directed therapeutic regimens used to treat DLBCL patients.